AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01303783 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 different placebo tablets corresponding nifedipine doses and 1 placebo capsule corresponding to candesartan doses
Study NCT01303783 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil (Atacand), 16 mg
Description: 16 mg of candesartan as capsule
Study NCT01303783 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil (Atacand), 32 mg
Description: 32 mg of candesartan as capsule
Study NCT02789631 — intervention group
Intervention type: OTHER
Intervention: assessment
Study NCT00392080 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CJ-023,423
Description: 75 mg BID
Study NCT00392080 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT00392080 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: naproxen
Description: naproxen
Study NCT02298023 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: allogenic adipose stem cell injection
Description: Intervention will be done with stem cell injection, 0.5cc (Total: 10 million cells), fibrin glue injection 0.5cc and range of motion exercise.
Study NCT02298023 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: fibrin glue/normal saline injection
Description: Total 1cc of fibin glue and normal saline mixture injection and range of motion exercise
Study NCT02298023 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: normal saline injection
Description: Total 1cc of normal saline injection and range of motion exercise
Study NCT03623555 — intervention group
Intervention type: BEHAVIORAL
Intervention: Trier Social Stress Test
Description: The participants are instructed to imagine having applied for their dream job and that they are now invited to a job interview. The TSST consists of three successive phases: (1) A preparation period (3min), (2) a free speech task in which the participants have to argue why they are the best candidate for the job they wish to apply for (5min), and (3) a mental arithmetic task in which participants have to sequentially subtract an odd two-digit number from an odd four-digit number (e.g., 17 from 2023; 5min). The two tasks are performed in front of a selection committee (two members), dressed in white lab coats, acting in a reserved manner and providing no facial or verbal feedback.
Study NCT03623555 — intervention group
Intervention type: BIOLOGICAL
Intervention: Salivary cortisol
Description: Saliva samples will be obtained by means of Salivette collection devices before, 10 minutes after, and 30 minutes after the beginning of the TSST
Study NCT02628938 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Miswak extract mouth wash
Description: 50% Miswak extract mouth wash (5ml) twice a day for 7 days
Study NCT02628938 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Miswak stick
Description: Miswak stick twice a day for 7 days
Study NCT02628938 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Chlorohexidine gluconate
Description: 5 ml of 0.2% Chlorohexidine gluconate mouth wash Oraxine ® twice a day for 7 days
Study NCT01398553 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Armeo Spring
Description: 30min Armeo Spring + 15min task oriented therapy over 6 weeks Frequency: 3 x/week
Study NCT01398553 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional physiotherapy
Description: 30min occupational therapy(15min ADL-training, 15min repetitive training) + 15min task oriented therapy over 6 weeks Frequency: 3x/week
Study NCT01578421 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: 4 h online hemodiafiltration (FX 100, Polyflux 210, FXCorDiax)
Description: 4 h online hemodiafiltration with measurement of clearance and removal rate by split dialysate collection and bloodside measurements
Study NCT03855228 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mometasone furoate nasal spray (MFNS)
Description: Daily dose of 200 µg of mometasone furoate administered as a nasal spray for 15 days.
Study NCT03855228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone furoate nasal spray (MFNS)
Description: Daily dose of 200 µg of mometasone furoate administered as a nasal spray for 15 days.
Study NCT03855228 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Loratadine
Description: Daily dose of 10 mg of loratadine administered as an oral tablet for 15 days.
Study NCT03855228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loratadine
Description: Daily dose of 10 mg of loratadine administered as an oral tablet for 15 days.
Study NCT03855228 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo nasal spray
Description: Daily dose of placebo administered as a nasal spray for 15 days.
Study NCT03855228 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo nasal spray
Description: Daily dose of placebo administered as a nasal spray for 15 days.
Study NCT03855228 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo tablet
Description: Daily dose of placebo administered as an oral tablet for 15 days.
Study NCT03855228 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablet
Description: Daily dose of placebo administered as an oral tablet for 15 days.
Study NCT03042325 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alogliptin
Description: Alogliptin tablets
Study NCT00722800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: drospirenone and ethinyl estradiol (YAZ)
Description: 1 tablet daily for 24 weeks
Study NCT00722800 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 tablet daily for 24 weeks
Study NCT03101787 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Extracorporeal cardiopulmonary resuscitation (ECPR)
Description: In addition to the routine response team, the ECLS team are called to the ED while the patient is transported to the hospital.~The team consists of a physician skilled and qualified in femoral cannulation, a perfusionist and a scrub nurse.~Upon the patient's arrival at the emergency department, CPR will be continued, with continuation of mechanical chest compressions with minimization of interruptions.~Time from arrest to start of cannulation is \< 60 minutes.
Study NCT02009306 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PecFent and Epistatus
Description: PecFent will be supplied by Archimedes Pharma as two strengths of nasal spray solution at 1000 or 4000 mcg/mL fentanyl (as citrate). One spray contains 100 mcg or 400 mcg fentanyl (as citrate). Each bottle contains 1.55 ml ensuring delivery of 8 sprays of 100 or 400 mcg fentanyl (as citrate). PecFent is a commercially available product and packaging will be in accordance with the manufacturing authorisations (EU/1/10/644/001, EU/1/10/644/002, EU/1/10/644/005, EU/1/10/644/003, EU/1/10/644/004, EU/1/10/644/006).~Epistatus will be supplied by Special Products Ltd. as buccal solution, packed in bottles containing solution for up to 4 x 1 ml doses, as per Specials licence. A pack also includes 4 x oral syringes used to administer the solution to the buccal cavity on either side of the mouth.
Study NCT02009306 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard subcutaneous medication
Description: Subcutaneous as needed medication will include:~* Opioids for pain or dyspnoea~  * Diamorphine~ * Oxycodone~ * Fentanyl~* Benzodiazepine and / or anti-psychotic for agitation~  * Midazolam~ * Levomepromazine~ * Haloperidol Anti-emetic for nausea~* Cyclizine~* Metoclopramide~* Haloperidol~* Levomepromazine~* Anti-secretory drug for respiratory secretions~* Glycopyrronium~* Hyoscine butylbromide~* Hyoscine hydrobromide
Study NCT02009306 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard subcutaneous medication
Description: Subcutaneous as needed medication will include:~* Opioids for pain or dyspnoea~  * Diamorphine~ * Oxycodone~ * Fentanyl~* Benzodiazepine and / or anti-psychotic for agitation~  * Midazolam~ * Levomepromazine~ * Haloperidol Anti-emetic for nausea~* Cyclizine~* Metoclopramide~* Haloperidol~* Levomepromazine~* Anti-secretory drug for respiratory secretions~* Glycopyrronium~* Hyoscine butylbromide~* Hyoscine hydrobromide
Study NCT02009306 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epistatus Alone
Description: Epistatus will be supplied by Special Products Ltd. as buccal solution, packed in bottles containing solution for up to 4 x 1 ml doses, as per Specials licence. A pack also includes 4 x oral syringes used to administer the solution to the buccal cavity on either side of the mouth.
Study NCT04308096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KRN23
Description: The starting dose of KRN23 will be the dose used for the last administration in the preceding studies. The dose may be modified subsequently in accordance with the criteria for dose and dose adjustment.
Study NCT01414608 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Brachytherapy
Description: Undergo brachytherapy
Study NCT01414608 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV
Study NCT01414608 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV
Study NCT01414608 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External Beam Radiation Therapy
Description: Undergo external beam radiation therapy
Study NCT01414608 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV
Study NCT01414608 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT01389271 — intervention group
Intervention type: DRUG
Intervention: Ventavis inhaled (Iloprost, BAYQ6256)
Description: Since this study is an observational, inhaled iloprost dosage and frequency for each patient will be prescribed by physicians as medically required.
Study NCT03949972 — intervention group
Intervention type: OTHER
Intervention: Biosampling
Description: Biosampling at initial visit and follow-up visits
Study NCT03645564 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Specialized nurse consultation
Description: The purpose of this consultation is to establish a partnership between the patient and the nursing staff. Tools were set up (notebook, movie) to answer the questions of the patient. In case of specific question, an expert will meet the patient (doctor of the service, psychologist, pharmacist or hematologist).
Study NCT02972853 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Training for Primary Care (MTPC)
Description: For intervention description see Mindfulness Training for Primary Care (MTPC) in the study MINDFUL-PC: Integrating Mindfulness Into the Patient-Centered Medical Home - A Pilot Study
Study NCT01491971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix
Study NCT03727607 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desflurane
Description: Desflurane vs TIVA, bariatric surgery. Postoperative nausea and pain
Study NCT02024555 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levofloxacin
Study NCT02024555 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ethambutol
Study NCT02024555 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin
Study NCT02024555 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifampin
Study NCT02024555 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: This will serve as a placebo to the antibiotics used in antimycobacterial therapy.
Study NCT02325648 — intervention group
Intervention type: DRUG
Intervention: HIPEC cytoreductive surgery
Description: At least 30 minutes prior to the prospective conclusion of the surgery, 1 μg/kg of fentanyl is administered for postoperative analgesia and 0.075mg of palonosetron is IV-infused for the prevention of nausea and vomiting. Desflurane and remifentanil administration is ceased after the surgery is concluded, muscle relaxation is evaluated by train of four (TOP) monitoring using a nerve stimulator, and the neuromuscular blockade is reversed with 0.2 mg of glycopyrrolate and 1 mg of neostigmine. When the patient recovers consciousness and begins spontaneous respiration, extubation is performed and the patient is transferred to the ICU with monitoring of their vital signs.
Study NCT02292342 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Water
Description: Control
Study NCT02292342 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Water
Description: Control
Study NCT02292342 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Epicatechin 0.1 mg/kg
Description: EC 0.1 mg/kg
Study NCT01304706 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluocinolone Acetonide
Description: 0.2 μg/day
Study NCT04638777 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: rTMS with H-coil
Description: Real repetitive transcranial magnetic stimulation with H-coil over M1 and PFC
Study NCT04638777 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: rTMS with H-coil
Description: Real repetitive transcranial magnetic stimulation with H-coil over M1 and sham repetitive transcranial magnetic stimulation with H-coil over PFC
Study NCT04638777 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: rTMS with H-coil
Description: Sham repetitive transcranial magnetic stimulation with H-coil over M1 and PFC
Study NCT02949817 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: digital rehabilitation system with wearable multi-IMU(inertial measurement unit) sensors (Rapael kids)
Description: 1.The Rapael kids, a video-game based rehabilitation therapy system using IMU sensors as a game interface, newly-developed in Korea will be used on upper limb function of children with pediatric brain injury patients. 20 of All 40 children will receive the conventional occupational therapy and additional video-game based rehabilitation therapy, 30 minutes daily 5 times per week, for 4 weeks.
Study NCT02292342 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Epicatechin 0.1 mg/kg
Description: EC 0.1 mg/kg
Study NCT02949817 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional OT group
Description: 2. Conventional OT group will recieve the conventional occupational therapy and one more conventional occupational therapy additionally. The additional occupational therapy training will be performed 30 minutes daily 5 times per week, for 4 weeks.
Study NCT02998827 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Study NCT02998827 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: infliximab, azathioprine
Description: other treatment include infliximab, azathioprine
Study NCT02998827 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: enteral nutrition
Study NCT02253186 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Auto-Adjustable MOBIDERM Armsleeve
Study NCT03446508 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active frontal
Description: 1) active HD-tDCS will be administered
Study NCT03446508 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active parietal
Description: 2) active HD-tDCS will be administered
Study NCT03446508 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: 3) sham HD-tDCS - no current
Study NCT03531905 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bempedoic acid + Ezetimibe FDC Oral Tablet
Description: Experimental therapy of bempedoic acid 180 mg + ezetimibe 10 mg FDC tablet
Study NCT03531905 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ezetimibe 10 mg Oral Tablet
Description: Ezetimibe 10 mg tablet, overencapsulated for blinding purposes
Study NCT03531905 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo tablet, matched for the FDC product for blinding purposes
Study NCT03531905 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo tablet, matched for the FDC product for blinding purposes
Study NCT03531905 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo oral capsule
Description: Placebo over-encapsulated for blinding purposes
Study NCT03531905 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Placebo over-encapsulated for blinding purposes
Study NCT01178242 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Salivary Gland and Labial Mucous Membrane Transplantation
Description: Minor salivary glands (SG) will be obtain en block from the same donor site, at the inferior or superior labial mucous membrane, above the orbicularis oris muscle to correct lubrication. The thin split thickness graft of mucous membrane will be suture to the sclera with absorbable sutures
Study NCT02379364 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Diacutaneous Fibrolysis
Description: Diacutaneous Fibrolysis is a non invasive physiotherapeutic technique applied by means a set of metallic hooks having the advantage of allowing a deeper and more precise application, which could not be achieved manually
Study NCT03882489 — intervention group
Intervention type: DRUG
Intervention: Isobaric 2-chloroprocaine
Description: The doses of isobaric 2-chloroprocaine will be administrated intrathecally and will be adjusted according to the observed responses in the previous subjects.
Study NCT02495376 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: MBSR
Description: Based primarily on the instruction of mindfulness meditation and yoga, MBSR is a group-based, 8-week program that was developed at the University of Massachusetts Stress Reduction Clinic under the direction of Jon Kabat-Zinn. MBSR is comprised of a structured, developmentally sequenced curriculum that uses a group format to experientially instruct participants in the practice of mindfulness meditation and mindful Hatha yoga. Each session includes different forms of meditation practice, such as cultivating awareness of thoughts, feelings and bodily sensations, and learning to incorporate this awareness during stressful emotional and/or physical life situations.
Study NCT01251614 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: Adalimumab by subcutaneous injection every other week (eow)
Study NCT01251614 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Methotrexate 0.1 mg/kg at Week 0 and up to 0.4 mg/kg per week (maximum dose of 25 mg/week) orally.
Study NCT01251614 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to Adalimumab
Description: A single subcutaneous loading dose at Week 0 followed by eow dosing beginning at Week 1.
Study NCT01251614 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Methotrexate
Description: Orally once a week
Study NCT03575962 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3640254 bis-hydrochloride salt capsule
Description: Administered orally (as single dose) on morning of Day 1, as 2 capsules of 100 mg following a moderate calorie and fat meal during Period 1 and Period 2, at the specified sequence, as per study.
Study NCT03575962 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3640254 Mesylate Salt Capsule
Description: Administered orally (as single dose) on morning of Day 1, as 2 capsules of , 100 mg following a moderate calorie and fat meal during Period 1 and Period 2, at the specified sequence, as per study.
Study NCT00878384 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Medication to control ventricular rate in AF
Description: Standard pharmacologic rate control. Current therapy will be adjusted to achieve rate-control targets of \<80bpm and \<110bpm on exercise (6 minute walk). Where necessary, additional medication will be given as per standard practice (digoxin or beta-blocker). Typical does: Digoxin 62.5-250mcg o.d. ; Bisoprolol 1.25-20mg o.d.; Carvedilol 3.125-50mg b.d. ; Nebivolol 1.25-10mg o.d.
Study NCT00878384 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Catheter Ablation for Persistent Atrial Fibrillation
Description: Radiofrequency catheter ablation, which may include pulmonary vein isolation, atrial substrate modification, and/or linear ablation.
Study NCT00713934 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD133
Description: portal vein infusion of CD133+ cells
Study NCT00713934 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BM-MNC
Description: portal vein infusion of BM-MNC
Study NCT02345200 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: bioelectrical impedance analysis
Description: electrophysical measurement that allows to determine the exact composition of single body compartments by producing a magnetic field and detecting the potential difference through the body
Study NCT02345200 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: blood draw
Description: blood samples are taken at 8 am in order to pay attention to the circadian rhythmicity to get a detailed hormonal status
Study NCT01626274 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LAVIMO in- ear sensor system
Description: Long term vital signs parameters like heart rate, heart rate variability, breathing and oxygen saturation are measured via in- ear sensor system during 1 polysomnographic night